NLRP3 and gout: Dapansutrile has been shown to be safe in humans, and Dapansutrile was the first NLRP3 inhibitor to complete two human proof-of-concept studies, one for acute gouty arthritis flares (Phase 2a) and one for stable systolic heart failure (NYHA II-III) (Phase 1b) (Aliaga et al., 2021).